Efinaconazole and Tavaborole
| Autor: | Jade D. Machin, Erin Dorval, Mara N. Poulakos, Yasmin Grace |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Antifungal medicine.medical_specialty Tavaborole medicine.drug_class business.industry 030106 microbiology Foot Dermatosis Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine Pharmacology (medical) business Efinaconazole medicine.drug |
| Zdroj: | Journal of Pharmacy Practice. 30:245-255 |
| ISSN: | 1531-1937 0897-1900 |
| DOI: | 10.1177/0897190016630904 |
| Popis: | Purpose: The purpose of this article is to review the safety, efficacy, and role of efinaconazole and tavaborole in the treatment of onychomycosis. Summary: Onychomycosis is a fungal infection of the nail caused by dermatophytes, yeasts, and nondermatophyte fungi. Distal and lateral subungual onychomycosis (DLSO) accounts for the majority of the cases. These infections cause structural damage to the nail which makes treatment difficult. Both oral and topical agents exist for the treatment of onychomycosis. Oral medications have generally been more effective, yet adverse effects and drug interactions limit their use in some patients. Food and Drug Administration (FDA)-approved agents in the United States for oral therapies include terbinafine, itraconazole, and griseofulvin. The only topical product available up to recently was ciclopirox. Conclusion: This article will review efinaconazole and tavaborole, 2 new topical antifungal agents released in 2014. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|